Your browser doesn't support javascript.
loading
The plasma miRNAome in ADNI: Signatures to aid the detection of at-risk individuals.
Krüger, Dennis M; Pena-Centeno, Tonatiuh; Liu, Shiwei; Park, Tamina; Kaurani, Lalit; Pradhan, Ranjit; Huang, Yen-Ning; Risacher, Shannon L; Burkhardt, Susanne; Schütz, Anna-Lena; Wan, Yang; Shaw, Leslie M; Brodsky, Alexander S; DeStefano, Anita L; Lin, Honghuang; Schroeder, Robert; Krunic, Andre; Hempel, Nina; Sananbenesi, Farahnaz; Blusztajn, Jan Krzysztof; Saykin, Andrew J; Delalle, Ivana; Nho, Kwangsik; Fischer, Andre.
Afiliación
  • Krüger DM; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Pena-Centeno T; Bioinformatics Unit, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Liu S; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Park T; Bioinformatics Unit, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Kaurani L; Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Pradhan R; Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Huang YN; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Risacher SL; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Burkhardt S; Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Schütz AL; Center for Computational Biology and Bioinformatics, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Wan Y; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Shaw LM; Research Group for Genome Dynamics in Brain Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Brodsky AS; Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • DeStefano AL; Perelman School of Medicine, Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
  • Lin H; Department of Pathology and Laboratory Medicine, Rhode Island Hospital, Warren Alpert Medical School at Brown University, Providence, Rhode Island, USA.
  • Schroeder R; Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts, USA.
  • Krunic A; Department of Medicine, UMass Chan Medical School, Worcester, Massachusetts, USA.
  • Hempel N; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Sananbenesi F; Department of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Blusztajn JK; Department for Epigenetics and Systems Medicine in Neurodegenerative Diseases, German Center for Neurodegenerative Diseases (DZNE), Göttingen, Germany.
  • Saykin AJ; Research Group for Genome Dynamics in Brain Diseases, German Center for Neurodegenerative Diseases, Göttingen, Germany.
  • Delalle I; Department of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
  • Nho K; Department of Radiology and Imaging Sciences and the Indiana Alzheimer's Disease Research Center, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Fischer A; Department of Pathology & Laboratory Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, Massachusetts, USA.
Alzheimers Dement ; 2024 Sep 18.
Article en En | MEDLINE | ID: mdl-39291752
ABSTRACT

INTRODUCTION:

MicroRNAs are short non-coding RNAs that control proteostasis at the systems level and are emerging as potential prognostic and diagnostic biomarkers for Alzheimer's disease (AD).

METHODS:

We performed small RNA sequencing on plasma samples from 847 Alzheimer's Disease Neuroimaging Initiative (ADNI) participants.

RESULTS:

We identified microRNA signatures that correlate with AD diagnoses and help predict the conversion from mild cognitive impairment (MCI) to AD.

DISCUSSION:

Our data demonstrate that plasma microRNA signatures can be used to not only diagnose MCI, but also, critically, predict the conversion from MCI to AD. Moreover, combined with neuropsychological testing, plasma microRNAome evaluation helps predict MCI to AD conversion. These findings are of considerable public interest because they provide a path toward reducing indiscriminate utilization of costly and invasive testing by defining the at-risk segment of the aging population. HIGHLIGHTS We provide the first analysis of the plasma microRNAome for the ADNI study. The levels of several microRNAs can be used as biomarkers for the prediction of conversion from MCI to AD. Adding the evaluation of plasma microRNA levels to neuropsychological testing in a clinical setting increases the accuracy of MCI to AD conversion prediction.
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Alzheimers Dement Año: 2024 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Estados Unidos